-Volume 37 | September 3, 2025
September is Childhood Cancer Awareness Month, and time for our annual Gold Bow Campaign! Get a bow to show your support and hope for families affected by osteosarcoma. This Childhood Cancer Awareness Month, we’re spotlighting the NCI’s Childhood Cancer Data Initiative (CCDI), which is transforming access to data to drive research and better care for kids with rare cancers like osteosarcoma. Medical professionals are invited to TURBO on September 10, a Zoom forum where global osteosarcoma experts review cases, share insights, and discuss trial options. The 2026 OutSmarting Osteosarcoma Research Grant, offering $100K Hero and $50K Young Investigator Hope Awards, opens for Letters of Intent submissions on September 24, 2025! Join us in driving hope, research, and awareness together.
With hope,
The MIB Agents Team
.png)
September is Childhood Cancer Awareness Month, and our annual Gold Bow campaign is a meaningful way to show your support. Gold Bows symbolize hope, courage, and solidarity with families impacted by osteosarcoma. With a donation of $25, Gold Bows can be proudly displayed on mailboxes, front doors, offices, schools, or anywhere special to you. More than decoration, they represent a promise: to push for better treatments for kids with cancer and honor the OsteoWarriors and OsteoAngels who inspire us. Our Bow Agents—volunteers who raise awareness and distribute Gold Bows in their communities—help this campaign shine even brighter. There’s still time to sign up if you’d like to volunteer! Order your Gold Bow kit today and help us shine a light on childhood cancer.
This September, in honor of Childhood Cancer Awareness Month, we're shining a light on the Childhood Cancer Data Initiative (CCDI), a groundbreaking effort by the NCI to revolutionize how data is collected, shared, and used in childhood cancer research and care. Our latest blog post explores how CCDI is unlocking new opportunities for discovery in rare pediatric cancers, such as osteosarcoma, by making comprehensive clinical, molecular, and patient-reported data more accessible and usable. Learn how researchers, clinicians, and families can get involved, and how the voice of the patient is helping to shape the future of precision medicine for kids and young adults with cancer.
- Pediatric Hematology/Oncology APRN- Sarcoma/Solid Tumor Program - Nicklaus Children’s
- Director, Solid Tumor Program - Penn State Children's Hospital
- Pediatric Hematology Oncology Faculty Position Sarcoma - Cleveland Clinic Children's
- Life Science Research Professional 1 - Kalbasi Lab, Stanford University
- Bioinformatician/Research Data Analyst 1 - Kalbasi Lab, Stanford University
- Assistant Professor, Sarcoma - OHSU
- Orthopedic Oncology Surgeon - OHSU
- Research Scientist, Osteosarcoma, Levi Lab - UT Southwestern
If you have a job posting and you would like it included here, please email christina@mibagents.org.
%20(2)%20(1).png)
If you’re managing a patient with relapsed osteosarcoma and want additional perspectives on treatment strategies or clinical trial options, consider presenting the case at MIB Agents TURBO (Tumor Review Board for Osteosarcoma). TURBO meets via Zoom every two months, bringing together a global panel of osteosarcoma experts to review complex cases, exchange insights, and discuss emerging data. It’s a collegial, multidisciplinary forum designed to support clinical decision-making for challenging cases. This educational forum is for medical professionals only; patients and families are welcome to ask their oncologists to present a case on their behalf.
Join TURBO to request an invite or submit a case.
- MRI-Based Radiomics for Outcome Stratification in Pediatric Osteosarcoma
.png)
Each of the 100 United States Senators have received an assembled bow listing the first name of every OsteoWarrior and OsteoAngel (known to MIB Agents) from their state on the #BecauseOf tag. We asked that the bows be displayed on their Washington, D.C. office doors in September. If you happen to spot a golden-yellow bow in one of the 3 Senate Office Buildings, please snap a picture and pass it along to emelia@mibagents.org.
Launched in 2017 and powered by MIB Agents Family Funds, the OutSmarting Osteosarcoma Research Grant has fueled discovery by awarding $2.5 million to 32 dedicated investigators working to advance osteosarcoma research. Our 2026 grant cycle will include two funding mechanisms. The OutSmarting Osteosarcoma Hero Award is a $100,000 grant, and the OutSmarting Osteosarcoma Young Investigator (YI) Hope Award is a $50,000 grant. New this year - open to investigators based in Canada! The Letter of Intent (LOI) submission period will open on September 24, 2025. LOIs are due by October 24, 2025 at 11:59pm ET. Approved LOI applicants will be invited to submit full applications by January 25, 2026.
Questions? Email christina@mibagents.org
Learn More About OutSmarting Osteosarcoma
The President’s proposed FY2026 budget cuts NIH funding by nearly 40%, threatening lifesaving cancer research and undermining the National Cancer Institute. With 77% of Americans opposing these cuts, now is the time to act. Tell Congress to reject these cuts, protect the NIH and NCI, and safeguard the future of science. Use AACR’s quick online form to contact your representatives today.
.png)
